TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00909129
Drug: pegylated interferon-alpha (Pegasys)
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
Study: NCT00909129
Drug: ribavirin (COPEGUS)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ribavirin bid 800-1200 mg depending on HCV genotype and body weight
Study: NCT00001010
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001010
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06341426
Drug: Single Psychedelic Dose Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
Study: NCT04974814
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
Study: NCT04720963
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intranasal remimazolam
Study: NCT04720963
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal dexmedetomidine
Study: NCT04777110
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
Study: NCT06454045
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg once a day for 14 days.
Study: NCT06241261
Drug: Silver diamine fluoride gel
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 38% SDF gel every 6 months
Study: NCT06241261
Drug: Silver diamine fluoride solution
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 38% SDF solution every 6 months
Study: NCT05336175
Drug: Angiotensin 1-7
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days.
Study: NCT05336175
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
Study: NCT05693077
Drug: Vancomycin Oral Capsule
Normalized name: vancomycin Oral Capsule
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 times a day 250mg
Study: NCT05070364
Drug: Peginterferon Lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulator
Study: NCT00435747
Drug: PARECOXIB SODIUM
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04769713
Drug: Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
Study: NCT00002145
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05389995
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7 days potassium citrate followed by 24 hour urine collection
Study: NCT05389995
Drug: Crystal light
Normalized name: kaolin light
DrugBank: Kaolin (DB01575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days crystal light followed by 24 hour urine collection
Study: NCT00000685
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05444946
Drug: Prednisone tablet and Itraconazole
Normalized name: itraconazole Oral Tablet
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
Study: NCT05444946
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
Study: NCT04781270
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg on day 1
Study: NCT04887506
Drug: Zytiga
Normalized name: Zytiga
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet, two tablets administered once daily
Study: NCT04887506
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
Study: NCT06366412
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.
Study: NCT05912114
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
Study: NCT05912114
Drug: Polyethylene glycol electrolyte
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
Study: NCT00002215
Drug: Emivirine
Normalized name: Emivirine
DrugBank: Emivirine (DB08188)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002215
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04761952
Drug: infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenously, at 0, 2,6 weeks with every 8-week-interval later
Study: NCT00002154
Drug: Thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002154
Drug: Selegiline hydrochloride
Normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04650698
Drug: Tranexamic acid (TXA) injection
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
Study: NCT04761952
Drug: N-3 Polyunsaturated Fatty Acids
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
Study: NCT05648487
Drug: HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy.
Study: NCT05722886
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05722886
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05722886
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adult and paediatric participants with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05722886
Drug: Trastuzumab in combination with pertuzumab
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The initial loading dose of trastuzumab is 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.~The initial loading dose of pertuzumab is 840 mg administered intravenously every 21 days followed thereafter by a maintenance dose of 420 mg.~Participants may continue until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05722886
Drug: Vemurafenib in combination with cobimetinib
Normalized name: Vemurafenib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05654233
Drug: Sulodexide
Normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
Study: NCT04037241
Drug: gemcitabine/nab paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: systemic chemotherapy regimen
Study: NCT04706936
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2/d
Study: NCT04706936
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2/d
Study: NCT04681053
Drug: Ivermectin Powder
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Administration through inhalation (6mg) BID for 3 days
Study: NCT05184322
Drug: T2026
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily for 15 days.
Study: NCT05184322
Drug: Oral ecnoglutide tablet
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 6 weeks.
Study: NCT05184322
Drug: Oral ecnoglutide tablet
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily and titrated up in concentration to once every week during maintenance period.
Study: NCT05184322
Drug: Oral ecnoglutide tablet
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 15 days.
Study: NCT05184322
Drug: T2026
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily for 6 weeks.
Study: NCT05184322
Drug: T2026
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily to once weekly for 12 weeks.
Study: NCT05675462
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1inhibitor
Study: NCT05675462
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TKI
Study: NCT06450236
Drug: Perampanel 10 MG
Normalized name: perampanel 10 MG
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of Perampanel Tablets 10mg
Study: NCT06450236
Drug: Fycompa 10Mg Tablet
Normalized name: Fycompa 10mg Tablet
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of Perampanel Tablets 10mg
Study: NCT06146478
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide given at an average dose of 1.5mg/kg/day
Study: NCT05053880
Drug: ACT001 + Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
Study: NCT05222204
Drug: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
Study: NCT03924102
Drug: Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A rest and stress imaging study will be conducted on the PET/CT scanner with \[11C\] Acetate.
Study: NCT05109000
Drug: Sodium Chloride 0.9% Inj
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL subcutaneous injection into one randomized anterior thigh of subject
Study: NCT05109000
Drug: Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)
Normalized name: bacteriostatic sodium chloride 0.9 % INJECTION VIAL (ML)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL subcutaneous injection into the contralateral anterior thigh of subject
Study: NCT05348408
Drug: platelet rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: perineural PRP injection under ultrasound guidance in addition to medical treatment
Study: NCT05900219
Drug: HL-085+Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
Study: NCT04855305
Drug: Hyperpolarized 129Xe
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
Study: NCT05575297
Drug: Rifampicin Sodium
Normalized name: Rifampicin sodium
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administration of methotrexate and rifampicin
Study: NCT05575297
Drug: Febuxostat Tablets
Normalized name: Febuxostat Tablets
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Co-administration of methotrexate and febuxostat
Study: NCT04953962
Drug: CBP501 (16)
DrugBank: CBP-501 (DB17277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/m2
Study: NCT04953962
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2
Study: NCT04953962
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg
Study: NCT00001057
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001057
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05391022
Drug: Pelabresib
Normalized name: Pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelabresib monohydrate tablets
Study: NCT04980716
Drug: Multiple cardiovascular drugs related to Golden Triangle
Normalized name: GOLDEN SEAL
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
Study: NCT04258683
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
Study: NCT05360628
Drug: D-0120 in combination with Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: noted above
Study: NCT05939817
Drug: Triamcinolone Acetonide (TA)
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Study: NCT00002001
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002001
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002001
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06319183
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
Study: NCT05321199
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.